DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,612,792 shares of the medical device company's stock after selling 404,874 shares during the period. DexCom makes up approximately 0.9% of Baillie Gifford & Co.'s investment portfolio, making the stock its 27th biggest holding. Baillie Gifford & Co. owned 3.74% of DexCom worth $1,136,437,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Allworth Financial LP lifted its stake in shares of DexCom by 60.9% during the fourth quarter. Allworth Financial LP now owns 1,081 shares of the medical device company's stock worth $84,000 after buying an additional 409 shares during the period. Principal Securities Inc. lifted its position in DexCom by 3.4% during the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company's stock valued at $316,000 after purchasing an additional 135 shares during the period. Congress Asset Management Co. lifted its position in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares during the period. Empire Life Investments Inc. lifted its position in DexCom by 6.6% during the fourth quarter. Empire Life Investments Inc. now owns 89,263 shares of the medical device company's stock valued at $6,942,000 after purchasing an additional 5,537 shares during the period. Finally, Bank Pictet & Cie Europe AG lifted its position in DexCom by 1.8% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after purchasing an additional 2,010 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DXCM stock traded down $0.34 on Thursday, reaching $89.34. 3,340,349 shares of the company were exchanged, compared to its average volume of 3,629,892. The company has a market cap of $34.90 billion, a price-to-earnings ratio of 62.48, a P/E/G ratio of 2.33 and a beta of 1.14. The business has a 50-day moving average price of $83.06 and a 200 day moving average price of $75.85. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. Equities research analysts forecast that DexCom, Inc. will post 2.02 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. The trade was a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,083 shares of company stock valued at $3,309,794. Corporate insiders own 0.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on DXCM shares. Wells Fargo & Company boosted their target price on shares of DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating for the company in a research report on Friday, October 25th. Raymond James decreased their target price on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating for the company in a research report on Friday, October 25th. Baird R W upgraded shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Finally, Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.